AURKA and Familial prostate cancer: Research has shown that the expression level of AURKA is upregulated in a variety of human cancers, including gastric, colorectal, hepatocellular, ovarian, renal, bladder, and prostate cancers, and that the high expression of AURKA is associated with clinical aggressiveness, poor prognosis, and treatment resistance, suggesting that AURKA has become an important biomarker and therapeutic target for the diagnosis and prognostic prediction of different cancers [31].